BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawanami D, Takashi Y, Takahashi H, Motonaga R, Tanabe M. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants (Basel) 2021;10:246. [PMID: 33562528 DOI: 10.3390/antiox10020246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Attimarad M, Venugopala KN, Nair AB, Sreeharsha N, Molina EIP, Kotnal RB, Tratrat C, Altaysan AI, Balgoname AA, Deb PK. Environmental sustainable mathematically processed UV spectroscopic methods for quality control analysis of remogliflozin and teneligliptin: Evaluation of greenness and whiteness. Spectrochim Acta A Mol Biomol Spectrosc 2022;278:121303. [PMID: 35525182 DOI: 10.1016/j.saa.2022.121303] [Reference Citation Analysis]
2 Ramos H, Bogdanov P, Huerta J, Deàs-just A, Hernández C, Simó R. Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy. Antioxidants 2022;11:1418. [DOI: 10.3390/antiox11071418] [Reference Citation Analysis]
3 Arab HH, Elhemiely AA, El-sheikh AAK, Khabbaz HJA, Arafa EA, Ashour AM, Kabel AM, Eid AH. Repositioning Linagliptin for the Mitigation of Cadmium-Induced Testicular Dysfunction in Rats: Targeting HMGB1/TLR4/NLRP3 Axis and Autophagy. Pharmaceuticals 2022;15:852. [DOI: 10.3390/ph15070852] [Reference Citation Analysis]
4 Ortenberg EA, Suplotova LA. Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review). Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-10-40-45] [Reference Citation Analysis]
5 Attimarad M, Venugopala KN, Chohan MS, David M, Molina EIP, Sreeharsha N, Nair AB, Tratrat C, Altaysan AI, Balgoname AA. An Experimental Design Approach to Quantitative Expression for Quality Control of a Multicomponent Antidiabetic Formulation by the HILIC Method. Molecules 2022;27:3135. [DOI: 10.3390/molecules27103135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Attimarad M, Venugopala KN, Al-Dhubiab BE, Elgorashe REE, Shafi S. Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation. Molecules 2021;26:6160. [PMID: 34684741 DOI: 10.3390/molecules26206160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Wang J, Xiang H, Lu Y, Wu T, Ji G. New progress in drugs treatment of diabetic kidney disease. Biomed Pharmacother 2021;141:111918. [PMID: 34328095 DOI: 10.1016/j.biopha.2021.111918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Okuma H, Mori K, Nakamura S, Sekine T, Ogawa Y, Tsuchiya K. Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice. Int J Mol Sci 2021;22:7329. [PMID: 34298949 DOI: 10.3390/ijms22147329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Alqurashi MY, Alharthi KF, Alshehri AA, Alharbi YK, Sanousi MA, Almazyed AA, Alghamdi KS, Alrashidi SM, Qaeed WA, Alasmari AA. The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease. Pharmacophore 2021;12:91-94. [DOI: 10.51847/m3fntokszv] [Reference Citation Analysis]